Acrivon Therapeutics (ACRV)
Acrivon Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
1.7M
Short interest
settlement 2026-10-15
6.6
Days to cover
+2.2 days vs prior
42.6%
Short share of volume
2026-11-02
194
Fails to deliver
settlement 2026-10-09
Thu 12 Nov
Next earnings
estimated date
-$39K
Insider flow, 90 days
0 buys, 9 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ACRV is 1,737,689 shares, up 535,070 shares over the last month. Over the last 48 readings it ranged from 561,817 shares (29 August 2025) to 7,521,144 shares (15 January 2026). At the reported average volume of 265K shares a day that is 6.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/acrv" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,737,689 | +7.5% | 264,538 | 6.57 |
| 2026-09-30 | 1,616,727 | +34.4% | 367,469 | 4.40 |
| 2026-09-15 | 1,202,619 | +5.6% | 243,602 | 4.94 |
| 2026-08-31 | 1,139,237 | -7.8% | 409,741 | 2.78 |
| 2026-08-14 | 1,235,893 | -8.8% | 305,473 | 4.05 |
| 2026-07-31 | 1,355,015 | -8.9% | 315,055 | 4.30 |
| 2026-07-15 | 1,487,445 | -47.6% | 636,379 | 2.34 |
| 2026-06-30 | 2,840,348 | +0.5% | 374,493 | 7.58 |
| 2026-06-15 | 2,827,334 | +0.9% | 346,461 | 8.16 |
| 2026-05-29 | 2,801,992 | +12.3% | 461,247 | 6.07 |
| 2026-05-15 | 2,496,168 | +1.3% | 563,211 | 4.43 |
| 2026-04-30 | 2,463,735 | +3.2% | 1,076,681 | 2.29 |
| 2026-04-15 | 2,388,157 | +9.3% | 573,503 | 4.16 |
| 2026-03-31 | 2,185,860 | -9.2% | 638,817 | 3.42 |
| 2026-03-13 | 2,407,914 | +12.8% | 848,502 | 2.84 |
| 2026-02-27 | 2,135,443 | -8.3% | 973,653 | 2.19 |
| 2026-02-13 | 2,327,887 | +15.0% | 726,050 | 3.21 |
| 2026-01-30 | 2,024,627 | -73.1% | 1,119,438 | 1.81 |
| 2026-01-15 | 7,521,144 | +41.2% | 5,799,928 | 1.30 |
| 2025-12-31 | 5,325,324 | +4.0% | 397,354 | 13.40 |
| 2025-12-15 | 5,121,709 | +17.6% | 493,692 | 10.37 |
| 2025-11-28 | 4,356,053 | +17.6% | 505,257 | 8.62 |
| 2025-11-14 | 3,702,932 | +114.7% | 2,071,401 | 1.79 |
| 2025-10-31 | 1,724,519 | +5.5% | 350,149 | 4.93 |
| 2025-10-15 | 1,635,281 | +42.0% | 456,361 | 3.58 |
| 2025-09-30 | 1,151,365 | -9.9% | 537,682 | 2.14 |
| 2025-09-15 | 1,277,862 | +127.5% | 6,648,289 | 1.00 |
| 2025-08-29 | 561,817 | -20.7% | 186,901 | 3.01 |
| 2025-08-15 | 708,420 | +1.7% | 176,207 | 4.02 |
| 2025-07-31 | 696,368 | +16.3% | 320,697 | 2.17 |
| 2025-07-15 | 598,604 | -21.6% | 279,556 | 2.14 |
| 2025-06-30 | 763,705 | -32.1% | 481,123 | 1.59 |
| 2025-06-13 | 1,124,785 | +7.5% | 550,602 | 2.04 |
| 2025-05-30 | 1,046,196 | -21.9% | 822,880 | 1.27 |
| 2025-05-15 | 1,338,911 | -3.9% | 655,286 | 2.04 |
| 2025-04-30 | 1,393,720 | +96.2% | 2,036,671 | 1.00 |
| 2025-04-15 | 710,505 | -19.9% | 371,562 | 1.91 |
| 2025-03-31 | 887,113 | +21.4% | 300,701 | 2.95 |
| 2025-03-14 | 730,574 | -2.4% | 23,966 | 30.48 |
| 2025-02-28 | 748,676 | -33.9% | 55,462 | 13.50 |
| 2025-02-14 | 1,132,370 | +3.1% | 105,546 | 10.73 |
| 2025-01-31 | 1,098,407 | -5.8% | 32,177 | 34.14 |
| 2025-01-15 | 1,166,074 | -0.9% | 40,690 | 28.66 |
| 2024-12-31 | 1,177,147 | +6.5% | 58,384 | 20.16 |
| 2024-12-13 | 1,105,728 | -0.7% | 64,652 | 17.10 |
| 2024-11-29 | 1,113,711 | +0.2% | 42,151 | 26.42 |
| 2024-11-15 | 1,111,317 | +3.0% | 53,131 | 20.92 |
| 2024-10-31 | 1,079,220 | -3.0% | 47,882 | 22.54 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ACRV volume is 42.6%, down 20.7 points over the last five sessions. Over the last 30 readings it ranged from 36.4% (28 October 2026) to 73.9% (29 September 2026). The latest reading is 10.6 points below the 30-session average of 53.2%, on 143K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 61K | 143K | 42.6% | 0 |
| 2026-10-30 | 64K | 96K | 66.2% | 0 |
| 2026-10-29 | 25K | 56K | 44.9% | 0 |
| 2026-10-28 | 32K | 87K | 36.4% | 0 |
| 2026-10-27 | 45K | 73K | 61.9% | 0 |
| 2026-10-26 | 106K | 168K | 63.3% | 0 |
| 2026-10-23 | 32K | 65K | 49.2% | 0 |
| 2026-10-22 | 21K | 39K | 54.1% | 0 |
| 2026-10-21 | 35K | 85K | 41.2% | 0 |
| 2026-10-20 | 41K | 89K | 46.2% | 0 |
| 2026-10-19 | 26K | 54K | 47.0% | 0 |
| 2026-10-16 | 68K | 146K | 46.6% | 510 |
| 2026-10-15 | 47K | 76K | 61.7% | 1 |
| 2026-10-14 | 86K | 124K | 69.6% | 3 |
| 2026-10-13 | 151K | 263K | 57.2% | 4,052 |
| 2026-10-12 | 44K | 80K | 54.3% | 0 |
| 2026-10-09 | 38K | 78K | 48.6% | 200 |
| 2026-10-08 | 96K | 168K | 57.3% | 0 |
| 2026-10-07 | 42K | 76K | 55.7% | 771 |
| 2026-10-06 | 42K | 78K | 54.3% | 0 |
| 2026-10-05 | 102K | 248K | 41.3% | 0 |
| 2026-10-02 | 64K | 124K | 52.1% | 0 |
| 2026-10-01 | 90K | 171K | 52.7% | 0 |
| 2026-09-30 | 40K | 87K | 45.9% | 4,922 |
| 2026-09-29 | 36K | 48K | 73.9% | 0 |
| 2026-09-28 | 58K | 103K | 56.2% | 0 |
| 2026-09-25 | 58K | 94K | 61.6% | 0 |
| 2026-09-24 | 80K | 144K | 55.5% | 0 |
| 2026-09-23 | 129K | 230K | 56.0% | 927 |
| 2026-09-22 | 125K | 294K | 42.5% | 7,500 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 9 October 2026, the fails-to-deliver balance in ACRV is 194 shares, down 37 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (3 August 2026) to 22,934 shares (14 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-09 | 194 | $1.87 | $363 |
| 2026-10-08 | 231 | $1.88 | $434 |
| 2026-10-07 | 192 | $1.86 | $357 |
| 2026-10-01 | 241 | $2.05 | $494 |
| 2026-09-29 | 213 | $2.06 | $439 |
| 2026-08-14 | 3,149 | $1.85 | $6K |
| 2026-08-03 | 1 | $1.50 | $2 |
| 2026-07-27 | 3,888 | $1.60 | $6K |
| 2026-07-10 | 2 | $2.05 | $4 |
| 2026-07-09 | 3,951 | $2.04 | $8K |
| 2026-06-26 | 3,081 | $1.58 | $5K |
| 2026-06-15 | 2,295 | $1.48 | $3K |
| 2026-06-09 | 312 | $1.41 | $440 |
| 2026-06-02 | 16,005 | $1.56 | $25K |
| 2026-05-27 | 2,245 | $1.67 | $4K |
| 2026-05-26 | 39 | $1.75 | $68 |
| 2026-05-21 | 1,980 | $1.76 | $3K |
| 2026-05-20 | 22,597 | $1.60 | $36K |
| 2026-05-18 | 3,081 | $1.77 | $5K |
| 2026-05-06 | 1,234 | $2.08 | $3K |
| 2026-05-04 | 3,044 | $2.09 | $6K |
| 2026-04-29 | 166 | $1.90 | $315 |
| 2026-04-23 | 17,340 | $1.97 | $34K |
| 2026-04-20 | 101 | $1.78 | $180 |
| 2026-04-17 | 347 | $1.67 | $579 |
| 2026-04-15 | 3,200 | $1.64 | $5K |
| 2026-04-14 | 22,934 | $1.61 | $37K |
| 2026-04-13 | 6,144 | $1.56 | $10K |
| 2026-03-31 | 2 | $1.29 | $3 |
| 2026-03-27 | 3,880 | $1.42 | $6K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ACRV reported 9 open-market sells worth $39K in the last 90 days and no open-market buys. Latest filing: Miller Mary (Chief Legal Officer) on 2026-10-22.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-22 | Miller Mary | Chief Legal Officer | Sell | 513 | $1.84 | $944 | 81K |
| 2026-10-05 | Miller Mary | Chief Legal Officer | Sell | 294 | $1.99 | $585 | 82K |
| 2026-08-31 | Levin Michaela | Chief Business Officer | Grant | 30K | $0.00 | $0 | 30K |
| 2026-08-25 | Blume-Jensen Peter | President and CEO | Sell | 14K | $2.21 | $31K | 2.2M |
| 2026-08-18 | Peterson Katharine | Chief Accounting Officer | Sell | 101 | $2.01 | $203 | 18K |
| 2026-08-18 | Miller Mary | Chief Legal Officer | Sell | 185 | $2.01 | $372 | 82K |
| 2026-08-18 | Gamelin Erick | Chief Development Officer | Sell | 400 | $2.01 | $804 | 53K |
| 2026-08-18 | Devroe Eric | Chief Operating Officer | Sell | 604 | $2.01 | $1K | 146K |
| 2026-08-18 | Blume-Jensen Peter | President and CEO | Sell | 484 | $2.01 | $973 | 386K |
| 2026-08-18 | Blume-Jensen Peter | President and CEO | Sell | 1K | $2.01 | $2K | 2.2M |
| 2026-08-04 | Levy Adam D. | Chief Financial Officer | Sell | 1K | $1.57 | $2K | 66K |
| 2026-07-21 | Miller Mary | Chief Legal Officer | Sell | 573 | $1.76 | $1K | 82K |
| 2026-05-21 | Masson Kristina | EVP - Business Operations | Tax withholding | 14K | $1.79 | $25K | 2.2M |
| 2026-05-21 | Blume-Jensen Peter | President and CEO | Tax withholding | 14K | $1.79 | $25K | 2.2M |
| 2026-05-18 | RA Capital Nexus Fund II, L.P. | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | TOMSICEK MICHAEL JOHN | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | Shacham Sharon | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | Palani Santhosh | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | Magovcevic-Liebisch Ivana | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | DiRocco Derek | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | BAUM CHARLES M | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2026-05-18 | Peterson Katharine | Chief Accounting Officer | Grant | 14K | $0.00 | $0 | 18K |
| 2026-05-18 | Mirza Mansoor Raza | Chief Medical Officer | Grant | 39K | $0.00 | $0 | 39K |
| 2026-05-18 | Miller Mary | Chief Legal Officer | Grant | 50K | $0.00 | $0 | 83K |
| 2026-05-18 | Levy Adam D. | Chief Financial Officer | Grant | 46K | $0.00 | $0 | 67K |
| 2026-05-18 | Gamelin Erick | Chief Development Officer | Grant | 39K | $0.00 | $0 | 53K |
| 2026-05-18 | Devroe Eric | Chief Operating Officer | Grant | 73K | $0.00 | $0 | 147K |
| 2026-05-18 | Blume-Jensen Peter | President and CEO | Grant | 73K | $0.00 | $0 | 386K |
| 2026-05-18 | Blume-Jensen Peter | President and CEO | Grant | 180K | $0.00 | $0 | 2.3M |
| 2026-05-14 | Peterson Katharine | Chief Accounting Officer | Tax withholding | 99 | $1.92 | $190 | 4K |
| 2026-05-14 | Miller Mary | Chief Legal Officer | Tax withholding | 184 | $1.92 | $353 | 33K |
| 2026-05-14 | Gamelin Erick | Chief Development Officer | Tax withholding | 404 | $1.92 | $776 | 14K |
| 2026-05-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 613 | $1.92 | $1K | 74K |
| 2026-05-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 490 | $1.92 | $941 | 314K |
| 2026-05-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 1K | $1.92 | $2K | 2.1M |
| 2026-04-22 | RA Capital Nexus Fund II, L.P. | Director | Grant | 3.9M | $1.80 | $7.0M | 11.8M |
| 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Grant | 3.9M | $1.80 | $7.0M | 11.8M |
| 2026-04-17 | Miller Mary | Chief Legal Officer | Tax withholding | 558 | $1.78 | $993 | 33K |
| 2026-02-21 | Blume-Jensen Peter | President and CEO | Tax withholding | 14K | $1.53 | $22K | 2.1M |
| 2026-02-14 | Peterson Katharine | Chief Accounting Officer | Tax withholding | 116 | $1.63 | $189 | 4K |
| 2026-02-14 | Miller Mary | Chief Legal Officer | Tax withholding | 217 | $1.63 | $354 | 34K |
| 2026-02-14 | Gamelin Erick | Chief Development Officer | Tax withholding | 471 | $1.63 | $768 | 15K |
| 2026-02-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 723 | $1.63 | $1K | 75K |
| 2026-02-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 579 | $1.63 | $944 | 314K |
| 2026-02-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 1K | $1.63 | $2K | 2.1M |
| 2026-01-17 | Miller Mary | Chief Legal Officer | Tax withholding | 659 | $1.98 | $1K | 34K |
| 2026-01-14 | Blume-Jensen Peter | President and CEO | Buy | 49K | $1.68 | $82K | 2.1M |
| 2026-01-14 | Levy Adam D. | Chief Financial Officer | Buy | 9K | $1.70 | $15K | 21K |
| 2026-01-13 | Devroe Eric | Chief Operating Officer | Buy | 10K | $1.72 | $17K | 75K |
| 2025-11-21 | Masson Kristina | EVP - Business Operations | Tax withholding | 20K | $2.30 | $46K | 2.0M |
| 2025-11-21 | Blume-Jensen Peter | President and CEO | Tax withholding | 20K | $2.30 | $46K | 2.0M |
| 2025-11-14 | Masson Kristina | EVP - Business Operations | Tax withholding | 60K | $2.24 | $134K | 2.1M |
| 2025-11-14 | Masson Kristina | EVP - Business Operations | Tax withholding | 490 | $2.24 | $1K | 315K |
| 2025-11-14 | Peterson Katharine | Chief Accounting Officer | Tax withholding | 99 | $2.24 | $222 | 4K |
| 2025-11-14 | Miller Mary | Chief Legal Officer | Tax withholding | 184 | $2.24 | $412 | 35K |
| 2025-11-14 | Gamelin Erick | Chief Development Officer | Tax withholding | 403 | $2.24 | $903 | 15K |
| 2025-11-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 613 | $2.24 | $1K | 65K |
| 2025-11-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 490 | $2.24 | $1K | 315K |
| 2025-11-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 60K | $2.24 | $134K | 2.1M |
| 2025-10-17 | Miller Mary | Chief Legal Officer | Tax withholding | 558 | $1.81 | $1K | 35K |
| 2025-10-01 | Miller Mary | Chief Legal Officer | Tax withholding | 284 | $1.81 | $514 | 35K |
| 2025-08-21 | Masson Kristina | EVP - Business Operations | Tax withholding | 20K | $1.32 | $26K | 2.1M |
| 2025-08-21 | Blume-Jensen Peter | President and CEO | Tax withholding | 20K | $1.32 | $26K | 2.1M |
| 2025-08-14 | Masson Kristina | EVP - Business Operations | Tax withholding | 60K | $1.39 | $83K | 2.1M |
| 2025-08-14 | Masson Kristina | EVP - Business Operations | Tax withholding | 490 | $1.39 | $681 | 315K |
| 2025-08-14 | Peterson Katharine | Chief Accounting Officer | Tax withholding | 99 | $1.39 | $138 | 4K |
| 2025-08-14 | Miller Mary | Chief Legal Officer | Tax withholding | 184 | $1.39 | $256 | 36K |
| 2025-08-14 | Gamelin Erick | Chief Development Officer | Tax withholding | 403 | $1.39 | $560 | 16K |
| 2025-08-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 613 | $1.39 | $852 | 66K |
| 2025-08-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 490 | $1.39 | $681 | 315K |
| 2025-08-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 60K | $1.39 | $83K | 2.1M |
| 2025-08-01 | Levy Adam D. | Chief Financial Officer | Tax withholding | 1K | $1.26 | $1K | 12K |
| 2025-07-17 | Miller Mary | Chief Legal Officer | Tax withholding | 558 | $1.32 | $737 | 36K |
| 2025-05-21 | Blume-Jensen Peter | President and CEO | Tax withholding | 20K | $1.15 | $23K | 2.2M |
| 2025-05-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 60K | $1.14 | $68K | 2.2M |
| 2025-05-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 491 | $1.14 | $560 | 316K |
| 2025-05-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 613 | $1.14 | $699 | 67K |
| 2025-05-14 | Gamelin Erick | Chief Development Officer | Tax withholding | 403 | $1.14 | $459 | 16K |
| 2025-05-14 | Miller Mary | Chief Legal Officer | Tax withholding | 184 | $1.14 | $210 | 36K |
| 2025-05-14 | Peterson Katharine | Chief Accounting Officer | Tax withholding | 99 | $1.14 | $113 | 4K |
| 2025-05-01 | PERCEPTIVE ADVISORS LLC | TenPercentOwner | Sell | 299K | $1.34 | $401K | 3.1M |
| 2025-04-30 | PERCEPTIVE ADVISORS LLC | TenPercentOwner | Sell | 438K | $1.41 | $617K | 3.4M |
| 2025-04-29 | PERCEPTIVE ADVISORS LLC | TenPercentOwner | Sell | 250K | $1.41 | $353K | 3.8M |
| 2025-04-28 | PERCEPTIVE ADVISORS LLC | TenPercentOwner | Sell | 215K | $1.56 | $336K | 4.1M |
| 2025-04-25 | PERCEPTIVE ADVISORS LLC | TenPercentOwner | Sell | 1.1M | $1.95 | $2.1M | 4.3M |
| 2025-04-17 | Miller Mary | Chief Legal Officer | Tax withholding | 558 | $1.81 | $1K | 37K |
| 2025-02-21 | Blume-Jensen Peter | President and CEO | Tax withholding | 20K | $5.54 | $110K | 2.3M |
| 2025-02-14 | Masson Kristina | EVP - Business Operations | Tax withholding | 579 | $5.42 | $3K | 316K |
| 2025-02-14 | Masson Kristina | EVP - Business Operations | Tax withholding | 37K | $5.42 | $201K | 2.3M |
| 2025-02-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 724 | $5.42 | $4K | 67K |
| 2025-02-14 | Gamelin Erick | Chief Development Officer | Tax withholding | 469 | $5.42 | $3K | 16K |
| 2025-02-14 | Holm-Jorgensen Rasmus | Chief Financial Officer | Tax withholding | 434 | $5.42 | $2K | 26K |
| 2025-02-14 | Miller Mary | Chief Legal Officer | Tax withholding | 217 | $5.42 | $1K | 37K |
| 2025-02-14 | Peterson Katharine | Chief Accounting Officer | Tax withholding | 116 | $5.42 | $629 | 4K |
| 2025-01-17 | Miller Mary | Chief Legal Officer | Tax withholding | 659 | $5.78 | $4K | 37K |
| 2024-11-21 | Masson Kristina | EVP - Business Operations | Tax withholding | 20K | $6.44 | $128K | 2.3M |
| 2024-11-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 490 | $7.92 | $4K | 317K |
| 2024-11-14 | Blume-Jensen Peter | President and CEO | Tax withholding | 60K | $7.92 | $473K | 2.4M |
| 2024-11-14 | Devroe Eric | Chief Operating Officer | Tax withholding | 613 | $7.92 | $5K | 68K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for ACRV worth $31K at the prices reported; 1 in the last 90 days worth $31K. Latest: Peter Blume-Jensen filed on 2026-08-25 to sell 14,036 shares ($31K) from 2026-08-25.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-25 | Peter Blume-JensenOfficer, Director | 14K | $31K | 0.033% | 2026-08-25 | Morgan Stanley Smith Barney LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of ACRV in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 28.8% of the class (12,284,906 shares), filed 2026-04-23 for an event on 2026-04-22.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 4 | Sands Capital Alternatives, LLCother entity | 2.3M | 5.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | SANDS FRANK M.individual, parent holding company | 2.3M | 5.3% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 4 | Sands Capital Life Sciences Pulse Fund II, L.P.partnership | 2.3M | 5.3% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Kenneth Griffinparent holding company, individual | 13 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Securities GP LLCparent holding company, other entity | 13 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Securities Group LPparent holding company, partnership | 13 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Securities LLCbroker-dealer, other entity | 13 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel GP LLCparent holding company, other entity | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Advisors Holdings LPparent holding company, partnership | 0 | 0.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 0 | 0.0% | 2026-03-31 |
| 2026-04-23 | 13D/Ano. 4 | RA Capital Management, L.P.investment adviser, partnership | 12.3M | 28.8% | 2026-04-22 |
| 2026-04-23 | 13D/Ano. 4 | Peter Kolchinskyparent holding company, individual | 12.3M | 28.8% | 2026-04-22 |
| 2026-04-23 | 13D/Ano. 4 | Rajeev Shahparent holding company, individual | 12.3M | 28.8% | 2026-04-22 |
| 2026-04-23 | 13D/Ano. 4 | RA Capital Healthcare Fund, L.P.partnership | 11.8M | 27.7% | 2026-04-22 |
13F holders
Tracked managers holding ACRV at their latest 13F. JSON3 of the 30 tracked managers held ACRV at their latest 13F, $2.6M in total at quarter-end prices. Renaissance Technologies is the largest at $1.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 759K | $1.4M | 0.00% | +423 |
| Two Sigma Investments | 2026-06-30 | 641K | $1.1M | 0.00% | +252K |
| Citadel Advisors | 2026-06-30 | 41K | $73K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Acrivon Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Acrivon Therapeutics (ACRV), SEC CIK 1781174, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-09.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-25.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-22.JSON and CSV
- Company record
- EDGAR filing index for CIK 1781174Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of ACRV is sold short?
1,737,689 shares were held short at the 2026-10-15 settlement, 6.6 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ACRV's daily short volume?
On 2026-11-02, 60,999 of the 143,338 ACRV shares reported to FINRA were sold short, 42.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ACRV have fails to deliver?
The SEC's latest file shows 194 ACRV shares failed to deliver at settlement 2026-10-09. Fails are reported per settlement date and published twice a month with a lag.
Are ACRV insiders buying or selling?
Insiders at ACRV reported 9 open-market sells worth $39K in the last 90 days and no open-market buys. Latest filing: Miller Mary (Chief Legal Officer) on 2026-10-22.
Have ACRV insiders filed to sell?
1 Form 144 notice on file for ACRV worth $31K at the prices reported; 1 in the last 90 days worth $31K. Latest: Peter Blume-Jensen filed on 2026-08-25 to sell 14,036 shares ($31K) from 2026-08-25.
Who owns 5% or more of ACRV?
7 holders report 5% or more of ACRV in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 28.8% of the class (12,284,906 shares), filed 2026-04-23 for an event on 2026-04-22.
Which tracked 13F managers own ACRV?
3 of the 30 tracked 13F managers held ACRV shares at their latest filing, $2.6M in all. The largest: Renaissance Technologies (759K shares, $1.4M), Two Sigma Investments (641K shares, $1.1M), Ken Griffin's Citadel Advisors (41K shares, $73K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.